NIDAN
Nidan Laboratories & Healthcare financials
- Market cap
- ₹18 Cr
- Sector
- Healthcare
What Nidan Laboratories & Healthcare Ltd does
Nidan Laboratories and Healthcare Limited provides healthcare and diagnostics services in India. The company's stated business expansion has been driven through a franchisee model, with the company sourcing new sites for centres as part of this growth.
- Permanent employees
- 163
Quarterly results
Q4 FY26: revenue up 0.6%, net profit up 101.4% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 10 | 12 | 12 | 11 −25% | 14 +37% | 13 +11% | 12 +1% |
| EBITDA | 5 | 2 | 3 | 3 | 3 −50% | 2 +50% | 3 −24% | 2 −26% |
| Net profit | 2 | 1 | 2 | -5 | 1 −53% | 1 −28% | 1 −26% | 0 +101% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −25.6% 1Y
1Y: ₹18.15 on 10 Sept 2025 → ₹13.5. High ₹22.8 (28 Nov 2025), low ₹12.5 (24 Jul 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹10 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr |
| Reserves | ₹3 Cr | ₹52 Cr | ₹56 Cr | ₹52 Cr | ₹56 Cr | ₹56 Cr |
| Borrowings | ₹38 Cr | ₹19 Cr | ₹11 Cr | ₹12 Cr | ₹13 Cr | ₹11 Cr |
| Other liabilities | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr |
| Total liabilities | ₹54 Cr | ₹88 Cr | ₹84 Cr | ₹83 Cr | ₹86 Cr | ₹84 Cr |
| Fixed assets | ₹20 Cr | ₹20 Cr | ₹21 Cr | ₹18 Cr | ₹16 Cr | ₹15 Cr |
| Capital work in progress | ₹0 Cr | ₹4 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹20 Cr | ₹20 Cr |
| Other assets | ₹33 Cr | ₹64 Cr | ₹63 Cr | ₹65 Cr | ₹50 Cr | ₹49 Cr |
| Total assets | ₹54 Cr | ₹88 Cr | ₹84 Cr | ₹83 Cr | ₹86 Cr | ₹84 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Mar 2025. The shareholder count shrank 9% to 2,359.
- Promoters
- 57.0%
- Public
- 43.0%
Since Mar 2025
- Promoters 0.00 pp
- Public 0.00 pp
How it drifted, 12 quarters
Over this window promoters fell from 71.2% to 57.0% — −14.2 pp.
Ownership split by quarter, oldest first. Nov '21: Promoters 71.2%, Public 28.8%.Mar '22: Promoters 71.2%, Public 28.8%.Sep '22: Promoters 71.2%, Public 28.8%.Mar '23: Promoters 71.2%, Public 28.8%.Sep '23: Promoters 62.8%, Public 37.2%.Mar '24: Promoters 57.0%, Public 43.0%.Sep '24: Promoters 57.0%, Public 43.0%.Mar '25: Promoters 57.0%, Public 43.0%.Sep '25: Promoters 57.0%, Public 43.0%.Dec '25: Promoters 57.0%, Public 43.0%.Mar '26: Promoters 57.0%, Public 43.0%.Jun '26: Promoters 57.0%, Public 43.0%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Nidan Laboratories & Healthcare Ltd above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Nitin Vitthalrao Thorve | 50.15% | unchanged |
| Roshan Nitin Thorve | 6.89% | unchanged |
| Ramegowda Sonnenahalli Omprakash Gowda | 1.12% | unchanged |
| Devendra Rajnikant Ladhani | 1.08% | unchanged |
| Vitthal Laxman Thorave | 0.00% | unchanged |
| Abhilasha Nitin Thorave | 0.00% | unchanged |
| Krupesh Deepak Thakur | 0.00% | unchanged |
| Lata Vitthal Hande | 0.00% | unchanged |
| Hariprit Nitin Thorave | 0.00% | unchanged |
| Tejal Anil Jayakar | 0.00% | unchanged |
| Edwin Francis Dabre | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Nidan Laboratories & Healthcare Ltd
Guides on how to read this kind of business and the numbers that matter.